Elijah J. Mun

Elijah J. Mun

Auto-generated profile, based on publicly available information

Elijah J. Mun

University of Washington, Department of Internal Medicine, Seattle, Washington.

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EMElijah J. Mun
Elijah J. Mun
HMHani Babiker, MD
Hani Babiker, MD
UWUri Weinberg
Uri Weinberg
EKEilon D. Kirson
Eilon D. Kirson
DHDaniel D. Von Hoff
Daniel D. Von Hoff
Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. Clin Cancer Res; 24(2); 266–75. ©2017 AACR.